Gyorgy Bator

发表

Investigation of the Experimental Pharmacokinetics of the Bis-Chlorinated Bis-pyridinium Mono-aldoxime Cholinesterase Reactivator K-868 in Rats

Jennifer O Adeghate, F. Darvas, G. Karvaly, 2021, The Open Medicinal Chemistry Journal.

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study

H. Lemij, D. Broadway, P. Kóthy, 2020, Advances in Therapy.

Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment

H. Lemij, J. Kirwan, E. Chen, 2022, Advances in Therapy.

Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).

Mujtaba A. Qazi, J. Levenson, M. Coote, 2020, Ophthalmology.

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.

Arthur D. Fu, Ajay E. Kuriyan, Rishi P. Singh, 2022, Lancet.

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

R. Shah, P. Campochiaro, S. Gupta, 2023, Japanese Journal of Ophthalmology.

Faricimab Treat-and-Extend for Diabetic Macular Edema: 2-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.

P. Campochiaro, C. Regillo, D. Rosberger, 2023, Ophthalmology.

Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial

S. Sivaprasad, C. Wykoff, G. Yancopoulos, 2024, The Lancet.

A phase III, multicentre, randomised, investigator-masked, cross-over, comparative, non-inferiority trial evaluating the efficacy and tolerability of generic preservative-free Latanoprost (Polpharma S.A.) compared to Xalatan® (Pfizer) in patients with ocular hypertension or primary open-angle glauco

Gyorgy Bator, Tamas Acs, Norbert Czumbel, 2024, BMC ophthalmology.